BHCM
HAE icon

Brevan Howard Capital Management’s Haemonetics HAE Stock Holding History

Brevan Howard Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,488
Closed -$1.04M – 2268
2026
Q1 		$1.04M Buy
18,488
+3,251
+21% +$212K 0.01% 875
2025
Q4 		$1.22M Sell
15,237
-29,310
-66% -$1.97M 0.01% 676
2025
Q3 		$2.17M Buy
44,547
+26,062
+141% +$1.61M 0.01% 519
2025
Q2 		$1.38M Sell
18,485
-6,157
-25% -$408K 0.01% 914
2025
Q1 		$1.57M Sell
24,642
-168
-0.7% -$11.4K 0.02% 361
2024
Q4 		$1.94M Buy
24,810
+19,890
+404% +$1.6M 0.01% 290
2024
Q3 		$395K Buy
4,920
+1,111
+29% +$89.8K ﹤0.01% 758
2024
Q2 		$315K Buy
+3,809
New +$335K ﹤0.01% 761

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's HAE Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 18,488 shares — an estimated $1.04M sold.

Brevan Howard Capital Management first reported a position in HAE in Q2 2024 and held it in 8 quarters. The position peaked at $2.17M in Q3 2025. 330 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 18,488 Haemonetics shares in Q2 2026, an estimated $1.04M.
  • Brevan Howard Capital Management first reported a position in Haemonetics in Q2 2024 and held it in 8 quarters.
  • Brevan Howard Capital Management's Haemonetics position peaked at $2.17M in Q3 2025.
  • 330 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.